Scholarlink

Background <p>Schizophrenia (SCZ) and major depressive disorder (MDD) share overlapping clinical features. We examined plasma neutrophil gelatinase-associated lipocalin (NGAL) in drug-naïve patients to investigate differences between diagnostic groups and their associations with clinical symptoms and cognitive performance.</p> Methods <p>We recruited 510 participants (246 with SCZ, 158 with MDD, and 106 healthy controls [HC]) from 2017 to 2025. Plasma NGAL was measured using ELISA. Cognition was assessed with MCCB (SCZ) and RBANS (MDD). We employed partial correlations and multiple linear regression (FDR-corrected) to examine NGAL-clinical and cognitive associations. Receiver operating characteristic (ROC) curves with five-fold cross-validation were used to evaluate diagnostic discrimination.</p> Results <p>Plasma NGAL levels differed significantly across groups (<i>P</i> &lt; 0.001): levels were highest in MDD, lowest in SCZ, with HC intermediate. Following Box-Cox transformation, partial Pearson correlation revealed that in SCZ, NGAL correlated consistently and negatively with core symptoms (Positive: <i>r</i> = -0.289, <i>P</i> &lt; 0.001; Negative: <i>r</i> = -0.138, <i>P</i> = 0.005), while remaining positively associated with general psychopathology (<i>r</i> = 0.185, <i>P</i> = 0.005) and cognitive domains. Ten-times repeated five-fold cross-validation demonstrated high discriminative utility for NGAL: the highest accuracy was achieved in distinguishing SCZ from MDD (AUC = 0.857), followed by SCZ versus others (AUC = 0.826) and MDD versus others (AUC = 0.805).</p> Conclusions <p>Our findings demonstrate a distinctive bidirectional profile in plasma NGAL levels, where elevations in MDD and reductions in SCZ reflect divergent immune dysregulation signatures at the early stages of these disorders. Within the Immune Response System (IRS)–Compensatory Immune-regulatory System (CIRS) framework, these results suggest a failure of compensatory neuroprotective mechanisms in SCZ compared to persistent inflammatory activation in MDD. Collectively, NGAL serves as a promising biological adjunct to enhance the objective differentiation between SCZ and MDD, though longitudinal studies are warranted to validate its predictive value across illness trajectories.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnosis-specific associations of plasma NGAL in drug-naïve schizophrenia and major depressive disorder: an exploratory cross-sectional study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月20日

查看全文
  • Boxuan Zhou,
  • Xiaoxiao Sun,
  • Xiaoli Wang,
  • Xue Zhang,
  • Qiao Su,
  • Shuo Wang,
  • Jiayue Wang,
  • Zhenning Feng,
  • Ying Xu,
  • Yonghui Zhang,
  • Jie Li

摘要

Background

Schizophrenia (SCZ) and major depressive disorder (MDD) share overlapping clinical features. We examined plasma neutrophil gelatinase-associated lipocalin (NGAL) in drug-naïve patients to investigate differences between diagnostic groups and their associations with clinical symptoms and cognitive performance.

Methods

We recruited 510 participants (246 with SCZ, 158 with MDD, and 106 healthy controls [HC]) from 2017 to 2025. Plasma NGAL was measured using ELISA. Cognition was assessed with MCCB (SCZ) and RBANS (MDD). We employed partial correlations and multiple linear regression (FDR-corrected) to examine NGAL-clinical and cognitive associations. Receiver operating characteristic (ROC) curves with five-fold cross-validation were used to evaluate diagnostic discrimination.

Results

Plasma NGAL levels differed significantly across groups (P < 0.001): levels were highest in MDD, lowest in SCZ, with HC intermediate. Following Box-Cox transformation, partial Pearson correlation revealed that in SCZ, NGAL correlated consistently and negatively with core symptoms (Positive: r = -0.289, P < 0.001; Negative: r = -0.138, P = 0.005), while remaining positively associated with general psychopathology (r = 0.185, P = 0.005) and cognitive domains. Ten-times repeated five-fold cross-validation demonstrated high discriminative utility for NGAL: the highest accuracy was achieved in distinguishing SCZ from MDD (AUC = 0.857), followed by SCZ versus others (AUC = 0.826) and MDD versus others (AUC = 0.805).

Conclusions

Our findings demonstrate a distinctive bidirectional profile in plasma NGAL levels, where elevations in MDD and reductions in SCZ reflect divergent immune dysregulation signatures at the early stages of these disorders. Within the Immune Response System (IRS)–Compensatory Immune-regulatory System (CIRS) framework, these results suggest a failure of compensatory neuroprotective mechanisms in SCZ compared to persistent inflammatory activation in MDD. Collectively, NGAL serves as a promising biological adjunct to enhance the objective differentiation between SCZ and MDD, though longitudinal studies are warranted to validate its predictive value across illness trajectories.